RxDoctor Payments Data

Jaymini Nayee

Optometrist · Marietta, GANPI 1447415732

Payments from drug & device makers

$2,760in general payments, 2019–2025

Across 85 payments — averaging $32.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$807
  • Glaukos Corporation$308
  • AbbVie$218
  • Oyster Point Pharma, Inc.$202
  • Alcon$193
  • Dompe US, Inc.$139
  • plus $892 from 12 others

What the payments were for

  • Food & beverage$2,760100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,760 in reported general payments places this provider in the 75th percentile of 1,285 optometrist providers in Georgia.

See all optometrist providers in Georgia

Medicare billing

Part B allowed, 2024
$3,719
Medicare patients
29
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine44$48,313
XiidraLifitegrast15$27,370
CequaCyclosporine15$19,462
LumiganBimatoprost26$15,476
Cyclosporine12$8,135
Timolol Maleate63$2,139
TafluprostTafluprost/Pf13$1,971
Latanoprost92$983
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat23$220
Dorzolamide Hcl15$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$218$63,78970 claims
Bausch & Lomb Americas Inc.Xiidra$118$27,37015 claims
Sun Pharmaceutical Industries Inc.Cequa$807$19,46215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,285 optometrist providers in Georgia.

Other optometrist in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →